Robert J. Hombach, a director at Embecta Corp. (), recently increased his holdings in the company through a significant stock purchase. On August 12, 2026, Mr. Hombach acquired 45,000 shares of Embecta common stock.
The shares were purchased at a weighted-average price of $4.9744, with individual transaction prices ranging from $4.955 to $4.985. The total value of these acquisitions amounted to $223,848. The timing of this insider purchase is notable, as the stock has surged 36% over the past week while still trading 52% below its level from six months ago.
Following this transaction, Mr. Hombach directly holds 109,587.208 shares of Embecta Corp. common stock. According to InvestingPro analysis, the stock appears undervalued at current levels, with management aggressively buying back shares—one of several key insights available in the comprehensive Pro Research Report covering EMBC and 1,400+ other US equities.
In other recent news, Embecta Corp. reported fiscal third-quarter 2026 results that exceeded Wall Street expectations. The company announced adjusted earnings of $0.56 per share on revenue of $271.7 million. Analysts had anticipated earnings of $0.27 per share and revenue of $254.22 million, making this a significant earnings surprise. Embecta also raised its full-year adjusted operating margin guidance to a range of 23.5% to 24%, up from its previous range of 22.25% to 23.25%. Despite a revenue decline of 8.1% from the previous year, the company showed a sequential improvement from the prior quarter, driven by effective cost controls and contributions from its Owen Mumford acquisition. The company also highlighted its expansion into auto-injectors and GLP-1-related opportunities. These developments reflect Embecta’s strategic focus on enhancing profitability and exploring new growth avenues.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Leave a comment